Lokus 9p21 deletion is one of the most common genetic changes in human cancer. Lokus 9p21 contains, among others, the gene encoding methylthioadenosine phosphorylase (MTAP), the only enzyme that degrades methylthioadenosine (MTA). MTAP deletion results in an accumulation of MTA in cells that induces inhibition of PRMT5 methyltransferase, a decrease in the symmetrical level of arginin dimethylation in proteins, and thus increased cell sensitivity to cell modulation of the activity of the methylsome of PRMT5. In 2016, several functionally related biological targets were selected as synthetically lethal targets with MTAP deletion (including MTAP deletion). MAT2A, MEP50, PRMT5). This means that cancer cells with MTAP deletion are particularly sensitive to inhibition of these proteins and gives hope for the development of targeted therapy for a large population of cancer patients (up to 15 %). The aim of the project is to develop and implement Selvita S.A.'s own activity, characterised at the level of Phase I of a candidate for a new generation oncological drug, which is targeted therapy based on synthetic lethality. As part of the project, we would like to focus on the coding of genes p16/MTAP. The proposed strategy assumes work on defined therapeutic objectives, including MAT2A enzyme and PRMT5 methylsome protein complex and phenotypic approaches. This will allow the selection of a clinical candidate with the greatest therapeutic potential, the greatest chances of success in clinical trials and partnering with a pharmaceutical company. Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014).